Search - tctmd.com

Displaying 501 - 520 of 795

Sort: Relevancy | Date

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, Rajesh V Swaminathan

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

Presenter: Stephen G. Ellis, John A. Ormiston, Pieter C. Smits

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Presenter: Stephen G. Ellis, John A. Ormiston, Evald H. Christiansen

October 11, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston

October 11, 2015

Presentation

Clinical Outcome of Titanium-Nitride-Oxide-Coated Cobalt-Chromium Stents

Presenter: Pasi P. Karjalainen

September 10, 2015

Presentation CICT 2015

Drug Eluting Femoral Stents Where does it fit in my practice?

Presenter: Yazan Khatib

July 31, 2015

Presentation CCVVC 2015

Stents with Biodegradable Polymer

Presenter: Augusto Pichard

June 19, 2015

Presentation CCVVC 2015

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Presenter: Craig M. Walker

June 18, 2015

Presentation CCVVC 2015

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Presenter: Suhail Dohad

June 18, 2015

Advertisement

Lessons From the TAXUS Liberté/Prasugrel Substudy

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Biomimetic Stents: Rationale and Current Clinical Results

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Clinical Outcome of Titanium-Nitride-Oxide-Coated Cobalt-Chromium Stents

Drug Eluting Femoral Stents Where does it fit in my practice?

Stents with Biodegradable Polymer

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content